The MAP kinase pathway has been shown to be active in many growth factor signaling systems, including that of prolactin (PRL). In our studies, the main objective was to examine the possible involvement of MEK kinases (Map/Erk kinase kinases) in PRL-stimulated mitogenic and lactogenic processes. We used the MEK kinase inhibitor PD 098059 to block MEK kinase activation in the Nb2 cell line and mammary gland explants derived from 12-to 14-day pregnancy mice. PD 098059 attenuated PRL-induced Nb2 cell mitogenesis at 10 WM and a maximum inhibition was observed at 100 WM. In cultured mammary tissues, PD 098059 at 100 WM had no effect on the PRL stimulation of lipid, casein and lactose synthesis and iodide uptake. Further, the growth-inhibitory effect of PD 098059 on Nb2 cells was ameliorated when the drug was removed from the culture medium, indicating that PD 098059 acts in a reversible manner. When MEK1 was immunoprecipitated from PD 098059 and/or PRL treated Nb2 cells, PRL-stimulated MEK1 kinase activity was directly inhibited by PD 098059 at concentrations employed in the culture experiments. PRL has no effect on the tyrosyl phosphorylation of MAP kinases in cultured mammary tissues derived from pregnant mice, whereas earlier we found that PRL stimulates the tyrosyl phosphorylation of all four MAP kinases in Nb2 cells. The results suggest that the MAP kinase pathway plays an important role in the PRL stimulation of Nb2 cell mitogenesis but is not involved in the PRL stimulation of milk product synthesis. ß 1998 Elsevier Science B.V. All rights reserved.
Introduction
In recent years, multiple signaling pathways have been shown to be involved in prolactin (PRL) regulation of milk product synthesis in the mammary gland and mitogenesis in Nb2 and mammary cells. These pathways include the synthesis of polyamines and prostaglandins [24] , as well as the activation protein kinase C via the phosphatidyl inositol pathway [1^4] . The MAP kinase pathway has been shown to play an important role in many growth factor signaling systems, including that of PRL in its mitogenic e¡ect on Nb2 cells [5, 6] and cultured mammary cells [7] .
In order to study further the PRL signaling pathways, two primary model systems were employed: Nb2 cells in which the mitogenic e¡ect of PRL is expressed, and the mouse mammary gland explant system in which the lactogenic e¡ects of PRL are expressed. The Nb2 cell line, the only cell line known to express the intermediate form of the PRL receptor [8] , is dependent on lactogenic hormone stimulation for continuous progression through the cell cycle [9] . To date, several kinases that are activated in response to PRL in Nb2 cells have been identi¢ed; these include protein kinase C [1^4], RAF1 [10] , JAK2 kinase [11^13], MAP kinase [14] , P 21ras [6] and the S6 kinase family [15, 16] . Further studies indicate that MAP kinase may represent an integration point of signal transduction where serine/threonine kinase pathways and tyrosine kinase pathway are merged [17] . The goal of the present studies was to characterize the upstream entities in the PRL regulation of the MAP kinases in the Nb2 cells, and to assess the role of the MAP kinase pathway in the di¡erentiative actions of PRL in the mammary gland.
PD 098059 is a speci¢c, noncompetitive MEK inhibitor [18] . It completely blocks NGF-induced neurite formation in PC-12 cells [19] , the IGF-1 activated mitogen protein kinase pathway [20] by inhibiting MAP kinase activity, and many other MAP kinase signaling systems. PD 098059 was thus employed to assess whether MAP kinase activation is required for both PRL stimulation of mitogenesis in Nb2 cells and milk product synthesis in cultured mammary cells.
Materials and methods

Materials
Stocks of Nb2 cells were provided by C.T. Beer (Cancer Control Agency, Vancouver, B.C., Canada). Midpregnant (10^14 days of pregnancy) Swiss^Web-ster mice were purchased from Harlan Laboratories (Indianapolis, IN). Ovine PRL (oPRL) (NIH-P-S-17) was a gift from NIDDK. Other materials were purchased from the following sources: cortisol from Charles P¢zer (New York, NY); Medium 199 Earle's salts, Hanks' balanced salt solution, Fischer's medium, AIM-V medium, fetal calf serum, and horse serum from Gibco Laboratories (Grand Island, NY); porcine insulin, penicillin, and streptomycin from Eli Lilly (Indianapolis, IN); [4, 
Nb2 cell culture
The PRL-dependent Nb2 cell line was grown in Fischer's medium supplemented with 10% fetal calf serum and 10% horse serum, 1.0U10
34 M 2-mercaptoethanol, 100 IU/l penicillin, and 100 Wg/ml streptomycin, as previously described. Incubation for 24 h in serum-free Fischer's media e¡ectively arrests growth at the G 0 /G 1 phase of the cell cycle. Once serum depletion was complete, cells were harvested and treated with oPRL.
Nb2 mitogenesis assay
Nb2 cells arrested at G 0 /G 1 in the cell cycle were resuspended in serum-free AIM-V (stationary media) at 1.3U10 5 cells/ml. Cell aliquots of 800 Wl were then distributed into 24-well plates, and increasing concentrations of PD 098059 in 100-Wl quantities were added. Next, either 500 pg/ml oPRL or`stationary media' were added in 100-Wl aliquots to bring the total volume of each sample to 1 ml. Incubation of cells was carried out for 72 h, after which cell number was determined using a Coulter counter. 
Mouse mammary gland explant preparation
Mammary gland explants were prepared as previ-ously described from mice that were pregnant 12^14 days [22] . Mice were killed by cervical dislocation; mammary glands were removed and placed in Hank's balanced salt solution. Explants (3^6 mg each) from each of 8^10 animals were prepared and placed on siliconized lens paper in 60-mm petri dishes containing 6 ml of Medium 199 Earle's salts with 1 Wg/ml insulin and 10 37 M cortisol. Next, tissues were incubated for 24 h at 37³C under humidi¢ed 95% air/5% CO 2 atmosphere prior to experimentation. All studies involving the preparation of mouse mammary gland explants were performed in compliance with the regulations of the Animal Care and Use Committee of Wayne State University.
Mouse mammary gland bioassays
After an initial 24-h incubation, M 199 media was aspirated from tissues and replaced with 4 ml of fresh M 199 containing 100 WM PD 098059 and/or 1 Wg/ml PRL. Incubations were then continued for an additional 24 h, after which the incorporation of radioactive precursors into macromolecules was determined. In experiments involving the rate of lactose synthesis, mammary gland tissues were exposed to 0.5 WCi/ml [5,6- 3 H]glucose for the last 2 h of incubation in order to pulse label lactose. Labeled lactose was separated from labeled glucose on TLC plates and the radioactivity quantitated. For experiments in which the rate of casein synthesis was determined, [ 3 H]leucine (0.5 WCi/ml) was added to culture medium for the ¢nal 2 h of incubation. Quantities of [ 3 H]leucine incorporated into the casein-rich phosphoprotein fraction were determined in a protein fraction isoelectrically precipitated at pH 4.6. In experiments determining the rate of lipid synthesis, tissues were exposed to [
14 C]acetate (0.5 WCi/ml) for the last 2 h of incubation. Tissues were then weighed, homogenized in 400 Wl of distilled water, and the lipids extracted by the method of Bligh and Dyer [28] . Radioactivity in the organic layer was then quantitated. Results are expressed as disintegrations per mg wet tissue weight. Finally, in experiments determining the rate of iodide uptake, tissues were transferred to vessels containing 125 I (0.25 WCi/ml, 0.3 ng/ml iodide) for the last 4 h of incubation. Tissues were then weighed and the amount of 125 I accumulated was quantitated (dpm/mg tissue weight).
Nb2 cell and mammary gland explant lysate preparations
Both G 1 -arrested Nb2 cells (1U10 6 /ml) and preincubated mouse mammary gland explants were treated with or without 25 WM PD 098059 and incubated for 24 h as described above. Samples were then washed twice with ice-cold phosphate-bu¡ered saline (PBS)^orthovanadate (1 mM). Nb2 cells were resuspended, at 4³C, in lysis bu¡er (2.0U10 7 cells/ml) containing 2% NP40, 10 mM Tris, 50 mM NaCl, 30 mM sodium pyrophosphate, 2.5 mM EDTA, 1 mM orthovanadate, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml aprotinin and 10 Wg/ml leupeptin, at pH 7.6. Mouse mammary gland explants were weighed, added to lysis bu¡er (1:2, w/v) and disrupted with a ground-glass homogenizer. After 30 min on a rocking platform, lysates were centrifuged (100 000Ug) for 30 min at 4³C. The resulting supernatants were used for immunoprecipitation and subsequently quantitated for total levels of MEK or MAP kinases in the prepared samples.
Immunoprecipitation and immunoblotting
After PRL and PD 098059 treatment, Nb2 cells (1U10 6 /ml) were washed through 4Uvolume of PBS^orthovanadate (1 mM) at 4³C by centrifugation (200Ug, 3 min) and resuspended in lysis bu¡er (2U10 7 /ml). The cleared lysate (1 ml), containing 3.7 mg protein/ml, was immunoprecipitated (overnight at 2³C) with either agarose-conjugated antiphosphotyrosine (UBI 16-101; 25 Wg monoclonal Ab/ml lysate), or anti-rat MAP kinase (UBI 06-182; 1 Wg/ml) followed by addition of 50 Wl protein A Sepharose beads (Pharmacia 17-0974-04). Proteins were solubilized in sodium dodecyl sulfate (SDS)L aemmli sample bu¡er, separated by SDS^poly-acrylamide gel electrophoresis (PAGE) (8^20% linear gradient) under reducing conditions and transferred to PVDF membranes (Schleicher and Schuell). Membranes were probed with horseradish peroxidase (HRP)-conjugated anti-phosphotyrosine (UBI 16-105; 20 ml at 1 Wg/ml) for 2 h or with anti-MAP kinase (UBI 06-182; 20 ml at 1 Wg/ml) for 2 h followed by treatment with anti-rat IgG HRP conjugate (Amersham NA934; 25 ml at 1:5000 dilution for 1.5 min). Detection was accom-plished by incubation with enhanced chemiluminescence reagents (Amersham) and exposure to X-ray ¢lm. MEK1 kinase activity was assessed according to the UBI protocol. Brie£y, the immunoprecipitated MEK1 enzyme was used to phosphorylate and activate recombinant p42 MAP kinase. Activated MAP kinase and [Q-32 P]adenosine triphosphate (ATP) were used to phosphorylate a speci¢c substrate, myelin basic protein. The phosphorylated substrates were separated from the residual [Q-32 P]ATP by di¡erential binding to p81 phosphocellulose paper. The radioactivity bound to the paper was quantitated in a liquid scintillation counter.
Statistical comparisons were made with Student's t-test for comparing two means, or with an analysis of variance followed by Sche¡e's test for multiple comparisons. Signi¢cant di¡erences (P 6 0.05) are indicated by asterisks in the ¢gures.
Results
In initial experiments, the e¡ect of increasing concentrations of PD 098059 on PRL-induced mitogenesis was determined in G 1 -arrested Nb2 cells. Fig. 1 shows that after 72 h of culture, PRL-stimulated proliferation is reduced by 50% when PD 098059 levels exceed 10 WM; maximum inhibition is observed at 100 WM. Control cell numbers are not signi¢cantly a¡ected by treatment with PD 098059 at any of the concentrations employed. DMSO, the solvent for PD 098059, was maintained below 0.05% and had no e¡ect on cell number (data not shown). Thus, these studies support a physiological role for MEK kinase in the PRL stimulation of mitogenesis in Nb2 cells since the MEK-speci¢c inhibitor suppressed the PRL response.
To characterize the e¡ect of PD 098059 on Nb2 Nb2 cells were washed three times with AIM-V medium and cultured for 24 h with 5 ng/ml PRL in the presence or absence 100 WM PD 098059 in 10 ml AIM-V medium. Cell numbers was then determined. The results represent mean þ S.E.M. of three observations. *P 6 0.01.
cell mitogenesis, several studies were carried out. Tables 1 and 2 contain the results of reversibility studies. Table 1 shows the 1-day PRL and/or PD 098059 e¡ect on Nb2 cell number. By itself, PRL doubled Nb2 cell number whereas in the presence of PD 098059 (100 WM), PRL-stimulated Nb2 cell mitogenesis is inhibited. Table 2 shows that a 24-h treatment of Nb2 cells with PD 098059 has no e¡ect on the subsequent mitogenic response to PRL during a further 72 h of culture. The PD 098059 inhibition is thus completely reversible. In order to further study the e¡ects of PD 098059 on Nb2 cell mitogenesis, a [ 3 H]thymidine incorporation experiment was carried out (Fig. 2) . After a 72-h culture, PD 098059 signi¢-cantly inhibited PRL-stimulated [ 3 H]thymidine incorporation in a concentration^response manner. Concentrations of PD 098059 above 20 WM abolished the PRL response.
To establish the e¤cacy of PD 098059 in inhibiting MEK activity, we examined the ability of this compound to inhibit PRL-stimulated MEK1 kinase activity. Fig. 3 shows that PD 098059 completely prevents the PRL stimulation of MEK1 activity.
To further con¢rm that PD 098059 speci¢cally blocks the PRL activation of MAP kinases, we examined the PD 098059 e¡ect on the tyrosine phosphorylation of the MAP kinase enzymes. Nb2 cells Nb2 cells (1U10 5 ) were cultured for 24 h as in Table 1 , washed with AIM-V, and then subcultured in 24-well plates for the next 72 h with or without 500 pg/ml PRL. The cell number was then determined. The results represent the mean þ S.E.M. of six observations. *P 6 0.01.
were treated with or without PD 098059 for 90 min as described above, followed by addition of 50 ng/ml oPRL for 10 min. Cells were lysed, and lysates were precipitated with either anti-MAP kinase R2 or antiphosphotyrosine antibodies. After SDS^PAGE and transfer to PVDF membranes, the blots were probed with an anti-phosphotyrosine antibody (Fig. 4A) . PRL clearly increases the tyrosyl phosphorylation of P 44 MAP and P 42 MAP (lane G) whereas inhibition is observed in the presence of PD 098059 (lane H). Fig. 4B displays the identical blot as Fig.  4A except it is probed with anti-MAP kinase antibody; the consistent amount of MAP kinases in each lane is apparent. In Fig. 4B , where anti-phosphotyrosine immunoprecipitates were probed with anti-MAP kinase antiserum, proteins from PRL-stimulated Nb2 cell lysates (lane C) exhibit an increase in anti-MAP kinase antibody binding, thus demonstrating that PRL increases MAP kinase tyrosine phosphorylation. This PRL-induced tyrosyl phosphorylation is totally inhibited by pretreatment with PD 098059 (lane D). Fig. 4C shows PRL has no e¡ect on MAP kinase tyrosyl phosphorylation in lysates derived from mouse mammary gland tissues.
The potential role of MAP kinase activation in the stimulation of milk product synthesis was examined in cultured mouse mammary tissues. Fig. 5 shows that PD 098059 has no e¡ect on PRL-stimulated glucose incorporation into lactose (Fig. 5A) or acetate incorporation into lipids (Fig. 5B) . As seen in Fig. 6 , PD 098059 at 100 WM also has no e¡ect on the PRL stimulation of iodide uptake (Fig. 6A ) or casein synthesis (Fig. 6B ) in cultured mammary tissues. These studies clearly show that PD 098059, a speci¢c MEK kinase inhibitor, has no e¡ect on the PRL stimulation of the synthesis of several milk products, whereas it completely abolishes the mitogenic e¡ect of PRL in Nb2 cells.
Discussion
Several important issues regarding PRL signaling 6 /ml) were incubated in the absence or presence of 100 WM PD 098059 for 90 min; 50 ng/ml oPRL was added for the ¢nal 10 min. Total cell lysate preparations were immunoprecipitated with anti-MEK1 kinase antibody. MEK1 kinase assay was carried out according to methods provided by UBI. *P 6 0.01. pathways are addressed in these studies. First, PRL was shown to stimulate MEK enzymatic activity in Nb2 cells. Since MEK is an upstream activator of the MAP kinases, the PRL stimulation of MEK is likely causally related to the PRL stimulation of the MAP kinases. These observations are consistent with earlier studies [7] where PRL was reported to stimulate MEK and MAP kinase activities in cultured neoplastic mammary cells. In further studies we found that the MEK inhibitor PD 098059 abolished the PRL stimulation of mitogenesis and [
3 H]thymidine incorporation in Nb2 cells, while at the same time this drug abolished the PRL e¡ects on MEK and MAP kinase enzymatic activities. The e¤cacy of the PD 098059 inhibition of MEK was clearly established. In addition, the PD 098059 inhibition of the PRL stimulation of mitogenesis in the Nb2 cells was shown to be completely reversible, thus suggesting that the PD 098059 does not express its e¡ect via a nonspeci¢c cytotoxic e¡ect on the cells. These studies thus clearly establish that the MEK^MAP kinase pathway is one of the integral signaling pathways involved in the PRL stimulation of mitogenesis in Nb2 cells. PD 098059 has been used in several earlier studies to study the involvement of MEK activation in the stimulation of mitogenesis in other cell systems [18, 19, 23, 24] .
Another important observation from these studies is that the di¡erentiative e¡ects of PRL on lactational processes in cultured mammary tissues [1^4, 21, 25, 26] do not appear to involve the MEKM AP kinase pathway. The MEK inhibitor PD 098059, at concentrations which e¡ectively inhibited MEK activity, had no in£uence on the PRL e¡ects on iodide transport, casein synthesis, lactose synthesis or lipid synthesis. In addition, PRL had no e¡ect on the tyrosyl phosphorylation of the MAP kinases in the cultured mammary tissues. This contrasts with the mitogenic e¡ects of PRL in Nb2 cells and cultured neoplastic mammary cells, where the MEKM AP kinase pathway is clearly involved in the PRL signaling pathway.
In a number of earlier studies [26] , several common signaling pathways have been shown to be involved in the PRL stimulation of mitogenesis and milk product synthesis. These include the polyamine, prostaglandin, phosphatidylinositol^protein kinase C and phosphatidylinositol 3-kinase pathways. The present studies clearly suggest that the MEK^MAP kinase pathway is speci¢cally involved only in the PRL stimulation of mitogenesis, but not in the lactational di¡erentiative PRL functions.
